<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oncology Product Guide &#187; generic Casodex</title>
	<atom:link href="http://www.oncologyproductguide.com/blog/tag/generic-casodex/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.oncologyproductguide.com/blog</link>
	<description>A comprehensive guide to oncology products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 12:00:01 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>FDA approves generic Casodex</title>
		<link>http://www.oncologyproductguide.com/blog/2009/07/08/fda-approves-generic-casodex/</link>
		<comments>http://www.oncologyproductguide.com/blog/2009/07/08/fda-approves-generic-casodex/#comments</comments>
		<pubDate>Thu, 09 Jul 2009 03:45:55 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Abbreviated New Drug Application]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Casodex]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[generic Casodex]]></category>
		<category><![CDATA[Sun Pharmaceutical]]></category>

		<guid isPermaLink="false">http://www.oncologyproductguide.com/blog/2009/07/08/fda-approves-generic-casodex/</guid>
		<description><![CDATA[The US FDA has approved the Abbreviated New Drug Application (ANDA) for generic Casodex Bicalutamide tablets to Sun Pharmaceutical Industries’ subsidiary. These bicalutamide tablets with strength of 50 milligram are therapeutically equivalent to Casodex tablets from AstraZeneca and are used in combination therapy with a lutenizing harmone-releasing harmone (LHRH) analog for the treatment of stage [...]]]></description>
			<content:encoded><![CDATA[<p><img src="http://www.oncologyproductguide.com/blog/wp-content/uploads/2009/07/casodex.png" align="right" vspace="5" width="200" height="152" hspace="5" />The US FDA has approved the Abbreviated New Drug Application (ANDA) for generic Casodex Bicalutamide tablets to Sun Pharmaceutical Industries’ subsidiary. These bicalutamide tablets with strength of 50 milligram are therapeutically equivalent to Casodex tablets from AstraZeneca and are used in combination therapy with a lutenizing harmone-releasing harmone (LHRH) analog for the treatment of stage D2 metastatic carcinoma of the prostate. The annual sales of the Casodex tablets are about $314 million in the US.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.oncologyproductguide.com/blog/2009/07/08/fda-approves-generic-casodex/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
